{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:26:36Z","timestamp":1787761596710,"version":"build-2784847793"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Synchronous multiple gastric cancers (SMGC) represent a rare clinical entity with no established treatment guidelines. We report a 76-year-old female with two synchronous poorly differentiated adenocarcinomas (dMMR\/MSI-H phenotype) in the gastric lesser curvature, clinically staged as cT4bN2M0. Following three cycles of neoadjuvant immunochemotherapy, the patient demonstrated remarkable tumor regression (RECIST 1.1 partial response) and subsequently underwent R0 distal gastrectomy. Histopathological examination confirmed a pathological complete response (ypT0N0, TRG 0).To our knowledge, this represents the first documented case of SMGC achieving pCR with neoadjuvant immunochemotherapy. Our findings suggest that PD-1 inhibition combined with chemotherapy may induce profound tumor regression in SMGC, even in cases with high tumor burden, potentially converting unresectable to resectable disease. This case provides compelling evidence for incorporating immunotherapy in SMGC management and warrants further investigation through clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1611281","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:10:29Z","timestamp":1752811829000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Pathological complete response achieved with neoadjuvant immunochemotherapy in synchronous multiple gastric adenocarcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Ya-hui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Wen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-hui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-jian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12809","article-title":"High risk of multiple gastric cancers in Japanese individuals with Lynch syndrome","volume":"8","author":"Kanaya","year":"2024","journal-title":"Ann Gastroenterol Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2017.109","article-title":"Characteristics of synchronous and metachronous multiple gastric tumors after endoscopic submucosal dissection of early gastric neoplasm","volume":"51","author":"Lee","year":"2018","journal-title":"Clin Endosc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10120-021-01269-3","article-title":"Gastric cancer exosomes contribute to the field cancerization of gastric epithelial cells surrounding gastric cancer","volume":"25","author":"Yoon","year":"2022","journal-title":"Gastric Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J Cell Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i41.7154","article-title":"Characteristics and prognosis of synchronous multiple early gastric cancer","volume":"19","author":"Isobe","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.6.873","article-title":"Clinicopathologic similarities of the main and minor lesions of synchronous multiple early gastric cancer","volume":"31","author":"Kim","year":"2016","journal-title":"J Korean Med Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.23922\/jarc.2020-064","article-title":"Immunotherapy in colorectal cancer: current and future strategies","volume":"5","author":"Ooki","year":"2021","journal-title":"J Anus Rectum Colon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01523-4","article-title":"Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair","volume":"27","author":"Ooki","year":"2024","journal-title":"Gastric Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v131.7","article-title":"Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis","volume":"131","author":"Liu","year":"2025","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102499","DOI":"10.1016\/j.compmedimag.2025.102499","article-title":"Interpretable multi-stage attention network to predict cancer subtype, microsatellite instability, TP53 mutation and TMB of endometrial and colorectal cancer","volume":"121","author":"Wang","year":"2025","journal-title":"Comput Med Imaging Graph"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03255-2","article-title":"Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer","volume":"44","author":"Liao","year":"2025","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.0242","article-title":"Molecular testing and targeted therapies in hepatobiliary cancers: A review","volume":"160","author":"Tsilimigras","year":"2025","journal-title":"JAMA Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3390\/cancers16193337","article-title":"Systemic therapy of gastric cancer-state of the art and future perspectives","volume":"16","author":"Lordick","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220491","article-title":"Analysis of characteristics and risk factors of patients with single gastric cancer and synchronous multiple gastric cancer among 14,603 patients","volume":"18","author":"Song","year":"2024","journal-title":"Gut Liver"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.704244","article-title":"Safety and efficacy of laparoscopic versus open gastrectomy in patients with advanced gastric cancer following neoadjuvant chemotherapy: A meta-analysis","volume":"11","author":"Liao","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T04:10:32Z","timestamp":1752811832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1611281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2025.1611281"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1611281","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"article-number":"1611281"}}